Priscila Sanabria

Priscila Sanabria

Auto-generated profile, based on publicly available information

Priscila Sanabria

Department of Physiology, Universidad Central del Caribe, Bayamón, Puerto Rico

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Brain Research Bulletin
Verified
Journal Article
Open access
LKLilia Kucheryavykh
Lilia Kucheryavykh
JDJosué Dávila-Rodríguez
Josué Dávila-Rodríguez
DRDavid Emanuel Rivera-Aponte
David Emanuel Rivera-Aponte
LZLidia V. Zueva
Lidia V. Zueva
A. Valance WashingtonA. Valance Washington
A. Valance Washington
Mikhail InyushinMikhail Inyushin
Mikhail Inyushin
Platelets contain beta-amyloid precursor protein (APP) as well as Aβ peptide (Aβ) that can be released upon activation. During thrombosis, platelets are concentrated in clots and activated. We used in vivo fluorescent analysis and electron microscopy in mice to determine to what degree platelets are concentrated in clots. We used immunostaining to visualize Aβ after photothrombosis in mouse brains. Both in vivo results and electron microscopy revealed that platelets were 300-500 times more concentrated in clots than in non-clotted blood. After thrombosis in control mice, but not in thrombocytopenic animals, Aβ immunofluorescence was present inside blood vessels in the visual cortex and around capillaries in the entorhinal cortex. The increased concentration of platelets allows enhanced release of Aβ during thrombosis, suggesting an additional source of Aβ in the brains of Alzheimer's patients that may arise if frequent micro-thrombosis events occur in their brains.

23 June 2009 in The Open Neuroscience Journal
Verified
Journal Article
Open access
PDF file
LKLilia Y. Kucheryavykh
Lilia Y. Kucheryavykh
YKYuriy V. Kucheryavykh
Yuriy V. Kucheryavykh
Mikhail InyushinMikhail Inyushin
Mikhail Inyushin
YSYaroslav M. Shuba
Yaroslav M. Shuba
PSPriscila Sanabria
Priscila Sanabria
MEMisty J. Eaton
Misty J. Eaton
Ischemia Increases TREK-2 Channel Expression in Astrocytes: Relevance to Glutamate Clearance

1 January 2015 in Neuropharmacology
Verified
Journal Article
Closed access
MVMaria C. Velásquez-Martínez
Maria C. Velásquez-Martínez
RVRafael Vázquez-Torres
Rafael Vázquez-Torres
LRLegier V. Rojas
Legier V. Rojas
PSPriscila Sanabria
Priscila Sanabria
CJCarlos Jimenez-Rivera
Carlos Jimenez-Rivera

5 September 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Mikhail InyushinMikhail Inyushin
Mikhail Inyushin
PSPriscila Sanabria
Priscila Sanabria
LRLegier Rojas
Legier Rojas
YKYuriy Kucheryavykh
Yuriy Kucheryavykh
LKLilia Kucheryavykh
Lilia Kucheryavykh
The amyloid beta (Aβ) peptide and its deposits in the brain are known to be implicated in the neurodegeneration that occurs during Alzheimer’s disease (AD). Recently, alternative theories views concerning both the source of this peptide and its functions have been developed. It has been shown that, as in all other known types of amyloidosis, the production of Aβoriginates in blood cells or cells related to blood plasma, from which it can then spread from the blood to inside the brain, with the greatest concentration around brain blood vessels. In this review, we summarize research progress in this new area and outline some future perspectives. While it is still unclear whether the main source of Aβdeposits in AD is the blood, the possibility of blocking the chain of reactions that lead to constant Aβrelease from the blood to the brain may be exploited in an attempt to reduce the amyloid burden in AD. Solving the problem of Aβaccumulation in this way may provide an alternative strategy for developing anti-AD drugs.

1 March 1996 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
NENelson Escobales
Nelson Escobales
MCMiriam Castro
Miriam Castro
PAPablo I. Altieri
Pablo I. Altieri
PSPriscila Sanabria
Priscila Sanabria
Simvastatin (SV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity inhibits migration and proliferation of vascular smooth muscle cells (SMC). To investigate whether these effects of SV are related to inhibition of cell calcium mobilization, cultured SMC obtained from rat aorta were loaded with Fura-2 to determine the basal cytosolic free calcium levels ([Ca2+]i) and the agonist-stimulated Ca2+ mobilization. SV (20 mu M) transiently increased cytosolic free calcium, an effect that depends mainly on intracellular calcium release (68%). This effect of SV was markedly reduced (75%) by thapsigargin, an inhibitor of the Ca2+ ATPase of inositol 1,4,5-triphosphate (InsP3)-sensitive calcium pools. Incubation of cells with SV (15 min) inhibited the mobilization of Ca2+ by angiotensin II, platelet-derived growth factor, and vasopressin (IC50 = 5 mu M). SV did not affect inositol trisphosphate (InsP3) levels or modify its generation by angiotensin II (Ang II) and vasopressin. Furthermore, in saponin-permeabilized cells, SV abolished the release of calcium by 2,3-dideoxy-InsP3. SV reduced the effect of thapsigargin on InsP3-sensitive stores by 67%, suggesting that SV depletes these calcium pools. The inhibitory effect of SV on calcium mobilization was prevented by coincubation of cultured cells (24 h) with 1 mM mevalonic acid, the product of HMG-CoA reductase activity. These results support the notion that SV inhibits [corrected] the migration and proliferation of SMC by directly affecting cell Ca2+.

1 February 2014 in Journal of Neuroscience and Neuroengineering
Verified
Journal Article
Closed access
LKLilia Kucheryavykh
Lilia Kucheryavykh
KRKimberleve Rolón-Reyes
Kimberleve Rolón-Reyes
YKYuriy Kucheryavykh
Yuriy Kucheryavykh
SSSerguei Skatchkov
Serguei Skatchkov
MEMisty J. Eaton
Misty J. Eaton
Mikhail InyushinMikhail Inyushin
Mikhail Inyushin
Organic cation transporters (OCTs) were first found and then isolated from cultured glioma cells. When glioma cells are implanted into brain the fate of OCTs varies with time after implantation and transporter type. Here we report that OCT1, OCT2 and OCT3 immunofluorescence is significantly reduced over time in implanted GL261 glioma cells, during tumor development in the brain. By day 21 after glioma implantation, OCT1, OCT2 and OCT3 immunofluorescence was reduced more than 10-fold in the cytoplasm of glioma cells, while OCT3 immunofluorescence became concentrated in the nucleus. The well-known fluorescent substrate for OCT transporters, 4-(4-(dimethylamino)-styryl)-N-methylpyridinium iodide (ASP+), previously shown to accumulate in glioma-cell cytoplasm in in vivo slices, began to accumulate in the nucleus of these cells, but not in cytoplasm, after 21 days post-implantation. Considering this mislocalization phenomenon, and other literature on similar nuclear mislocalization of different transporters, receptors and channels in glioma cells, we suggest that it is one of the “omens” preceding the motility and aggressivity changes in glioma behavior.